Table 4 Reimbursement adequacy index and social health insurance system
From: International comparison of the factors influencing reimbursement of targeted anti-cancer drugs
UK | Canada | Australia | Sweden | France * | Japan | Korea | Taiwan | Germany * | |
|---|---|---|---|---|---|---|---|---|---|
Reimbursement adequacy index | 0.79 | 0.68 | 0.63 | 0.58 | 0.58 | 0.58 | 0.53 | 0.53 | 0.47 |
Financing system | 76% General tax +18% National insurance +3% user charge | 100% General tax | 98.5% General tax +1.5% Levy | 100% General tax | 33% General tax +43% National insurance + Levies + other social security | Premium | Premium | Premium | Premium |
Health technology assessment (HTA) | Government independent | Government independent | Government agency | Government agency | Government agency | N/A | Government agency | Government agency | Government independent |
Date of HTA foundation | 1999 | 1990 | 1993 | 1987 | 2004 | N/A | 2009 | 2007 | 2004 |
Form of Health Security | National Healthcare Service | Social Health Insurance | Social Health Insurance | National Healthcare Service | Social Health Insurance | Social Health Insurance | Social Health Insurance | Social Health Insurance | Social Health Insurance |